

```
=> s hsdavftdnytrlrkqvaakkylqsiknkry/sqsp
L1      39 HSDAVFTDNYTRLRKQVAKKYLOSIKNKRY/SQSP
```

```
=> file hcaplus
COST IN U.S. DOLLARS
```

SINCE FILE	TOTAL
ENTRY	SESSION
29.80	30.01

FILE 'HCAPLUS' ENTERED AT 11:23:44 ON 28 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 27 Jun 2007 (20070627/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1
L2

13 L1

```
=> s l2 and (zinc or zn) and ((dimethyl(w)sulfoxide) or DMSO)
629465 ZINC
    139 ZINCS
629491 ZINC
        (ZINC OR ZINCS)
480710 ZN
    28400 ZNS
502633 ZN
        (ZN OR ZNS)
356915 DIMETHYL
    47 DIMETHYLS
356939 DIMETHYL
        (DIMETHYL OR DIMETHYLS)
38366 SULFOXIDE
11396 SULFOXIDES
42140 SULFOXIDE
        (SULFOXIDE OR SULFOXIDES)
15400 DIMETHYL(W)SULFOXIDE
49395 DMSO
    3 DMSOS
49395 DMSO
        (DMSO OR DMSOS)
L3      1 L2 AND (ZINC OR ZN) AND ((DIMETHYL(W)SULFOXIDE) OR DMSO)
```

=> d 13

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:656793 HCAPLUS
DN 139:202489

TI Formulation strategies in stabilizing peptides in organic solvents and in dried states
 IN Wang, Wei; Wang, Yu-Chang John; Martin-Moe, Sheryl
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068805	A2	20030821	WO 2003-US4790	20030214
	WO 2003068805	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472956	A1	20030821	CA 2003-2472956	20030214
	AU 2003219787	A1	20030904	AU 2003-219787	20030214
	EP 1476178	A2	20041117	EP 2003-716061	20030214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514914	T	20060518	JP 2003-567931	20030214
	US 2005009739	A1	20050113	US 2004-500680	20040701
PRAI	US 2002-356915P	P	20020214		
	WO 2003-US4790	W	20030214		

=> s 12 and (transition(w)metal) and (organic(w)solvent)
 991640 TRANSITION
 264357 TRANSITIONS
 1104967 TRANSITION
 (TRANSITION OR TRANSITIONS)
 1752731 METAL
 875002 METALS
 2119167 METAL
 (METAL OR METALS)
 186852 TRANSITION(W)METAL
 383963 ORGANIC
 3911 ORGANICS
 386487 ORGANIC
 (ORGANIC OR ORGANICS)
 1022430 ORG
 15913 ORGS
 1028209 ORG
 (ORG OR ORGS)
 1134971 ORGANIC
 (ORGANIC OR ORG)
 704724 SOLVENT
 341634 SOLVENTS
 881854 SOLVENT
 (SOLVENT OR SOLVENTS)
 149970 ORGANIC(W)SOLVENT
 L4 1 L2 AND (TRANSITION(W)METAL) AND (ORGANIC(W)SOLVENT)

=> d 14

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:656793 HCAPLUS
 DN 139:202489
 TI Formulation strategies in stabilizing peptides in *organic solvents* and in dried states
 IN Wang, Wei; Wang, Yu-Chang John; Martin-Moe, Sheryl
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068805	A2	20030821	WO 2003-US4790	20030214
	WO 2003068805	A3	20040226		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472956	A1	20030821	CA 2003-2472956	20030214
	AU 2003219787	A1	20030904	AU 2003-219787	20030214
	EP 1476178	A2	20041117	EP 2003-716061	20030214
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514914	T	20060518	JP 2003-567931	20030214
	US 2005009739	A1	20050113	US 2004-500680	20040701
PRAI	US 2002-356915P	P	20020214		
	WO 2003-US4790	W	20030214		

=> d 12 1-13

L2 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:473906 HCAPLUS
 TI HIV-1 integration is inhibited by stimulation of the VPAC2 neuroendocrine receptor
 AU Bokaei, Payman Baradar; Ma, Xue-Zhong; Sakac, Darinka; Branch, Donald R.
 CS Institute of Medical Science, University of Toronto, Toronto, ON, M5G 2M1, Can.
 SO Virology (2007), 362(1), 38-49
 CODEN: VIRLAX; ISSN: 0042-6822
 PB Elsevier
 DT Journal
 LA English
 RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:161820 HCAPLUS
 DN 146:394322
 TI Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo
 AU Pan, Clark Q.; Li, Fugang; Tom, Irene; Wang, Wei; Dumas, Michael; Froland, Wayne; Yung, Stephanie L.; Li, Yaxin; Rocznik, Steve; Claus, Thomas H.; Wang, Y. John; Whelan, James P.
 CS Biotechnology, Bayer Healthcare, Berkeley, CA, USA
 SO Journal of Pharmacology and Experimental Therapeutics (2007), 320(2), 900-906

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1099691 HCAPLUS

DN 145:432605

TI Preparation of vasoactive intestinal polypeptide analog for use in
treating metabolic conditions

IN Nestor, John

PA USA

SO U.S. Pat. Appl. Publ., 69pp., Cont.-in-part of U.S. Ser. No. 245,499.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006234933	A1	20061019	US 2006-279238	20060410
	US 2006079456	A1	20060413	US 2005-245499	20051007
	AU 2005294125	A1	20060420	AU 2005-294125	20051007
	WO 2006042152	A2	20060420	WO 2005-US36235	20051007
	WO 2006042152	A3	20070518		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	WO 2007044591	A2	20070419	WO 2006-US39267	20061006
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-617500P	P	20041008		
	US 2005-245499	A2	20051007		
	WO 2005-US36235	A	20051007		
	US 2006-279238	A	20060410		

L2 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:195898 HCAPLUS

DN 144:286712

TI Selective pegylated VPAC2 receptor peptide agonists for treating diabetes

IN Bokvist, Bengt Krister; Mayer, John Philip; Zhang, Lianshan;

Alsina-Fernandez, Jorge; Vick, Andrew Mark

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 236 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006023358	A1	20060302	WO 2005-US28531	20050811
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2577010	A1	20060302	CA 2005-2577010	20050811
	EP 1781694	A1	20070509	EP 2005-784310	20050811
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	US 2004-602350P	P	20040818		
	US 2004-602461P	P	20040818		
	WO 2005-US28531	W	20050811		
OS	MARPAT 144:286712				

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:194266 HCAPLUS
DN 144:286711
TI Selective pegylated VPAC2 receptor peptide agonists for treating diabetes
IN Bokvist, Bengt Krister; Mayer, John Philip; Zhang, Lianshan; Alsina-Fernandez, Jorge; Vick, Andrew Mark
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 496 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006023356	A2	20060302	WO 2005-US28520	20050811
	WO 2006023356	A3	20060518		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2577326	A1	20060302	CA 2005-2577326	20050811
	EP 1781692	A2	20070509	EP 2005-784171	20050811
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRAI US 2004-602350P P 20040818
US 2004-602461P P 20040818
WO 2005-US28520 W 20050811
OS MARPAT 144:286711

L2 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1260605 HCAPLUS
DN 144:17595
TI Selective VPAC2 receptor peptide agonists
IN Bokvist, Bengt Krister; Cummins, Robert Chadwick; Glaesner, Wolfgang;
Gromada, Jesper Lindgren; Mayer, John Philip; Zhang, Lianshan;
Alsina-Fernandez, Jorge
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 400 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113594	A1	20051201	WO 2005-US17435	20050519
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2564740	A1	20051201	CA 2005-2564740	20050519
	EP 1756156	A1	20070228	EP 2005-755072	20050519
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2004-573739P	P	20040521		
	US 2004-627880P	P	20041112		
	US 2005-656601P	P	20050225		
	WO 2005-US17435	W	20050519		

OS MARPAT 144:17595

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1259793 HCAPLUS
DN 144:32250
TI Selective VPAC2 receptor peptide agonists for diabetes treatment
IN Bokvist, Bengt Krister; Cummins, Robert Chadwick; Glaesner, Wolfgang;
Gromada, Jesper Lindgren; Mayer, John Philip; Zhang, Lianshan;
Alsina-Fernandez, Jorge
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113593	A1	20051201	WO 2005-US17434	20050519
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

CA 2567635 A1 20051201 CA 2005-2567635 20050519
EP 1753780 A1 20070221 EP 2005-749168 20050519

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRAI US 2004-573080P P 20040521
WO 2005-US17434 W 20050519

OS MARPAT 144:32250

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:160814 HCAPLUS

DN 142:254621

TI Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3)
agonists and their therapeutic use for type II diabetes and respiratory
disease

IN Pan, Clark; Tsutsumi, Manami; Shanafelt, Armen B.

PA Bayer Pharmaceuticals Corporation, USA

SO U.S. Pat. Appl. Publ., 123 pp., Division of U.S. Ser. No. 671,773.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PT	US 2005043237	A1	20050224	US 2004-892981	20040715
	US 6972319	B1	20051206	US 2000-671773	20000927
PRAI	US 2000-671773	A3	20000927		
	US 1999-240954P	P	19990928		
	US 2000-327556P	P	20000615		

L2 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:14261 HCAPLUS

DN 142:114733

TI Polymer derivatives having particular atom arrangements in a linking
group, their preparation, and use in compositions and as conjugates

IN Harris, J. Milton; Kozlowski, Antoni; McManus, Samuel P.; Bentley, Michael
D.; Charles, Stephen A.

PA Nektar Therapeutics AL, Corporation, USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000360	A2	20050106	WO 2004-US16212	20040521
	WO 2005000360	A3	20050728		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004251602 A1 20050106 AU 2004-251602 20040521
 CA 2510040 A1 20050106 CA 2004-2510040 20040521
 EP 1626741 A2 20060222 EP 2004-753099 20040521
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 CN 1747748 A 20060315 CN 2004-80004064 20040521
 JP 2007500278 T 20070111 JP 2006-533335 20040521
 PRAI US 2003-473213P P 20030523
 WO 2004-US16212 W 20040521

L2 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:917654 HCAPLUS
 DN 141:389078
 TI Differential regulation of activity-dependent neuroprotective protein in
 rat astrocytes by VIP and PACAP
 AU Zusev, Margalit; Gozes, Illana
 CS Sackler School of Medicine, Department of Clinical Biochemistry, Tel Aviv
 University, Tel Aviv-Jaffa, 69978, Israel
 SO Regulatory Peptides (2004), 123(1-3), 33-41
 CODEN: REPPDY; ISSN: 0167-0115.
 PB Elsevier B.V.
 DT Journal
 LA English
 RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:656793 HCAPLUS
 DN 139:202489
 TI Formulation strategies in stabilizing peptides in organic solvents and in
 dried states
 IN Wang, Wei; Wang, Yu-Chang John; Martin-Moe, Sheryl
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068805	A2	20030821	WO 2003-US4790	20030214
	WO 2003068805	A3	20040226		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472956	A1	20030821	CA 2003-2472956	20030214
	AU 2003219787	A1	20030904	AU 2003-219787	20030214
	EP 1476178	A2	20041117	EP 2003-716061	20030214
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514914	T	20060518	JP 2003-567931	20030214
	US 2005009739	A1	20050113	US 2004-500680	20040701
PRAI	US 2002-356915P	P	20020214		

L2 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:335562 HCAPLUS
 DN 137:257484
 TI A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: A potential therapy for type 2 diabetes
 AU Tsutsumi, Manami; Claus, Thomas H.; Liang, Yin; Li, Yaxin; Yang, Ling; Zhu, Jian; Dela Cruz, Fernando; Peng, Xianbu; Chen, Hongxing; Yung, Stephanie L.; Hamren, Sarah; Livingston, James N.; Pan, Clark Q.
 CS Department of Metabolic Disorders Research, Pharmaceutical Division, Bayer Corporation, West Haven, CT, USA
 SO Diabetes (2002), 51(5), 1453-1460
 CODEN: DIAEAZ; ISSN: 0012-1797
 PB American Diabetes Association
 DT Journal
 LA English
 RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:247368 HCAPLUS
 DN 134:290749
 TI Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use in treating metabolic disorders and respiratory disease
 IN Pan, Clark; Tsutsumi, Manami; Shanafelt, Armen B.
 PA Bayer Corporation, USA
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001023420	A2	20010405	WO 2000-US26638	20000927
	WO 2001023420	A3	20010830		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2379604	A1	20010405	CA 2000-2379604	20000927
	EP 1192182	A2	20020403	EP 2000-967002	20000927
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	HU 200202175	A2	20021028	HU 2002-2175	20000927
	RU 2269354	C2	20060210	RU 2001-136014	20000927
	CZ 296858	B6	20060712	CZ 2002-1085	20000927
	TW 264438	B	20061021	TW 2000-89120330	20000928
PRAI	US 1999-407832	A	19990928		
	US 2000-595280	A	20000615		
	WO 2000-US26638	W	20000927		

=> s pacap or (pacap-like (w)peptide)
 2599 PACAP
 64 PACAPS
 2601 PACAP

(PACAP OR PACAPS)
 2599 PACAP
 64 PACAPS
 2601 PACAP
 (PACAP OR PACAPS)
 799534 LIKE
 324 LIKES
 799802 LIKE
 (LIKE OR LIKES)
 77 PACAP-LIKE
 (PACAP(W)LIKE)
 372920 PEPTIDE
 273103 PEPTIDES
 477611 PEPTIDE
 (PEPTIDE OR PEPTIDES)
 8 PACAP-LIKE (W)PEPTIDE
 L5 2601 PACAP OR (PACAP-LIKE (W)PEPTIDE)

=> s 15 and (transition(w)metal) and (organic (w)solvent)

991640 TRANSITION
 264357 TRANSITIONS
 1104967 TRANSITION
 (TRANSITION OR TRANSITIONS)
 1752731 METAL
 875002 METALS
 2119167 METAL
 (METAL OR METALS)
 186852 TRANSITION(W)METAL
 383963 ORGANIC
 3911 ORGANICS
 386487 ORGANIC
 (ORGANIC OR ORGANICS)
 1022430 ORG
 15913 ORGS
 1028209 ORG
 (ORG OR ORGS)
 1134971 ORGANIC
 (ORGANIC OR ORG)
 704724 SOLVENT
 341634 SOLVENTS
 881854 SOLVENT
 (SOLVENT OR SOLVENTS)
 149970 ORGANIC (W)SOLVENT
 L6 1 L5 AND (TRANSITION(W)METAL) AND (ORGANIC (W)SOLVENT)

=> d 16

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:656793 HCAPLUS
 DN 139:202489
 TI Formulation strategies in stabilizing peptides in **organic solvents** and in dried states
 IN Wang, Wei; Wang, Yu-Chang John; Martin-Moe, Sheryl
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2003068805	A2	20030821	WO 2003-US4790	20030214
	WO 2003068805	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2472956 A1 20030821 CA 2003-2472956 20030214
 AU 2003219787 A1 20030904 AU 2003-219787 20030214
 EP 1476178 A2 20041117 EP 2003-716061 20030214
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006514914 T 20060518 JP 2003-567931 20030214
 US 2005009739 A1 20050113 US 2004-500680 20040701
 PRAI US 2002-356915P P 20020214
 WO 2003-US4790 W 20030214

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	63.08	93.09

FILE 'REGISTRY' ENTERED AT 11:33:45 ON 28 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0
 DICTIONARY FILE UPDATES: 27 JUN 2007 HIGHEST RN 939702-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s h...../sqsp
 L7 4472388 H...../SQSP

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.15	124.24

FILE 'HCAPLUS' ENTERED AT 11:36:10 ON 28 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jun 2007 VOL 147 ISS 1
FILE LAST UPDATED: 27 Jun 2007 (20070627/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7 and (transition(w)metal) and (organic(w) solvent)
TOO MANY TERMS FOR FILE CROSSOVER IN L7

There are limits on the size of an answer set being crossed over from one file to another. Enter HELP CROSSOVER at an arrow prompt (=>) for specific information.

=> help crossover

The term 'file crossover' refers to the use of an answer set L-number created by a search in one file as a search term or profile in another file. There are four types of crossovers in HCAplus: query crossover, accession number crossover, crossover from the Registry File, and crossover of extracted terms.

The query is searched in HCAplus when you search the L-number answer set created in another file, except for CASREACT, MARPAT, and Registry.

Accession numbers are crossed over when you search an L-number answer set from MARPAT in HCAplus or when you search an L-number answer set from HCAplus in MARPAT.

You may use the CAS Registry Numbers(R) that are answers from a search in the REGISTRY File as a search term or profile in the HCAplus File, without looking at all the answers or entering the Registry Numbers individually. To do this, enter the L-number of the REGISTRY answer set in a SEARCH command in HCAplus. You may use this L-number in any search where you might use a Registry Number, i.e., combined with other terms using the logical operators or the (L) operator. Registry Numbers crossed over from the REGISTRY File include all deleted (DR), replacing (RR), preferred (PR) and alternate (AR) numbers.

CAS Registry Numbers appended by D or DP are automatically searched whenever CAS Registry Numbers are crossed over. The suffix D indicates a generic or unspecified derivative, and DP indicates the preparation of generic derivatives. If you do not want to search CAS Registry Numbers for nonspecific derivatives, append the crossover L-number with /RN.

Examples (where L3 is an answer set from the REGISTRY File):

Search term	Retrieves
=> S L3	All CAS Registry numbers, including those appended with D or DP

=> S L3/RN

All CAS Registry Numbers,
excluding those appended with D or DP

Additionally, the REGISTRY File answer set may be qualified by a code for a CAS Role. Enter HELP ROLES at an arrow prompt (=>) in this file to obtain a list of role codes and their definitions.

Example of a search for Registry Numbers with the role code ANT for the role of "analyte" (where L3 is an answer set from the REGISTRY File):

=> S L3/ANT

There is a limit of 300,000 answers for a single crossover of CAS Registry Numbers. For information on how to transfer more than 300,000 CAS Registry Numbers from the REGISTRY File, enter HELP CROSSOVER at an arrow prompt in REGISTRY.

You may also crossover and search a set of terms extracted from an answer set.

To crossover records from HCAplus to CAOLD, use SELECT or TRANSFER with the OREF field. The OREF (Original Reference Number) field contains the Original Reference Number(s) for any record published in printed CA in 1907-1966. The format of OREF is the volume number of CA, colon, column number and fraction designation for the location of the entire bibliographic record and the abstract on the page of printed CA.

Enter HELP OREF for an example of a crossover from HCAplus to CAOLD. For more information on crossover of extracted terms, enter HELP TRANSFER at an arrow prompt.

```
=> s adrenocorticotrophic(w)hormone
      5617 ADRENOCORTICOTROPIC
        1 ADRENOCORTICOTROPICS
      5618 ADRENOCORTICOTROPIC
          (ADRENOCORTICOTROPIC OR ADRENOCORTICOTROPICS)
      292660 HORMONE
      215890 HORMONES
      402157 HORMONE
          (HORMONE OR HORMONES)
L8      5120 ADRENOCORTICOTROPIC(W)HORMONE
```

```
=> s l8 and (transition(w)metal) and (organic(w)solvent)
      991640 TRANSITION
      264357 TRANSITIONS
      1104967 TRANSITION
          (TRANSITION OR TRANSITIONS)
      1752731 METAL
      875002 METALS
      2119167 METAL
          (METAL OR METALS)
      186852 TRANSITION(W)METAL
      383963 ORGANIC
        3911 ORGANICS
      386487 ORGANIC
          (ORGANIC OR ORGANICS)
      1022430 ORG
        15913 ORGS
      1028209 ORG
          (ORG OR ORGS)
```

1134971 ORGANIC
 (ORGANIC OR ORG)
 704724 SOLVENT
 341634 SOLVENTS
 881854 SOLVENT
 (SOLVENT OR SOLVENTS)
 149970 ORGANIC(W) SOLVENT
 L9 1 L8 AND (TRANSITION(W) METAL) AND (ORGANIC(W) SOLVENT)

=> s prooriocortin
 0 PROORIOCORTIN
 L10 0 PROORIOCORTIN

=> s proopiocortin
 141 PROOPIOCORTIN
 1 PROOPIOCORTINS
 L11 142 PROOPIOCORTIN
 (PROOPIOCORTIN OR PROOPIOCORTINS)

=> s l11 and (zinc or zn)
 629465 ZINC
 139 ZINCS
 629491 ZINC
 (ZINC OR ZINCS)
 480710 ZN
 28400 ZNS
 502633 ZN
 (ZN OR ZNS)
 L12 0 L11 AND (ZINC OR ZN)

=> s l1 and (metal)
 13 L1
 1752731 METAL
 875002 METALS
 2119167 METAL
 (METAL OR METALS)
 L13 1 L1 AND (METAL)

=> d l13

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:656793 HCAPLUS
 DN 139:202489
 TI Formulation strategies in stabilizing peptides in organic solvents and in dried states
 IN Wang, Wei; Wang, Yu-Chang John; Martin-Moe, Sheryl
 PA Bayer Pharmaceuticals Corporation, USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068805	A2	20030821	WO 2003-US4790	20030214
	WO 2003068805	A3	20040226		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,	
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2472956	A1 20030821	CA 2003-2472956 20030214
AU 2003219787	A1 20030904	AU 2003-219787 20030214
EP 1476178	A2 20041117	EP 2003-716061 20030214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
JP 2006514914	T 20060518	JP 2003-567931 20030214
US 2005009739	A1 20050113	US 2004-500680 20040701
PRAI US 2002-356915P	P 20020214	
WO 2003-US4790	W 20030214	

=> d his

(FILE 'HOME' ENTERED AT 11:22:41 ON 28 JUN 2007)

FILE 'REGISTRY' ENTERED AT 11:23:04 ON 28 JUN 2007
L1 39 S HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY/SQSP

FILE 'HCAPLUS' ENTERED AT 11:23:44 ON 28 JUN 2007
L2 13 S L1
L3 1 S L2 AND (ZINC OR ZN) AND ((DIMETHYL(W)SULFOXIDE) OR DMSO)
L4 1 S L2 AND (TRANSITION(W)METAL) AND (ORGANIC(W)SOLVENT)
L5 2601 S PACAP OR (PACAP-LIKE (W)PEPTIDE)
L6 1 S L5 AND (TRANSITION(W)METAL) AND (ORGANIC (W)SOLVENT)

FILE 'REGISTRY' ENTERED AT 11:33:45 ON 28 JUN 2007
L7 4472388 S H...../SQSP

FILE 'HCAPLUS' ENTERED AT 11:36:10 ON 28 JUN 2007
L8 5120 S ADRENOCORTICOTROPIC(W)HORMONE
L9 1 S L8 AND (TRANSITION(W)METAL) AND (ORGANIC(W)SOLVENT)
L10 0 S PROORIOCORTIN
L11 142 S PROOPIOCORTIN
L12 0 S L11 AND (ZINC OR ZN)
L13 1 S L1 AND (METAL)